Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ASCO imaging guideline: NGI should be offered when salvage RT is contemplated after RP (evidence high, strong); withhold it when no salvage local therapy is planned.
A guidance-only day, no trial readouts. Prostate carried most: ASCO ties NGI to a salvage RT decision, an ESTRO ACROP Delphi reached consensus on only 14/40 salvage SBRT items, and an RSS case guide covers intact-prostate SBRT. Gyn: ABS HDR compendium keeps a cervix HR-CTV D90 goal of 85-95 Gy EQD210; ESGO/ESTRO/ESP backs universal MMR/MSI testing.
read the full digest →Studies · 251
- ESGO/ESTRO/ESP endometrial carcinoma guidelinesJoint European guideline update: universal MMR IHC or MSI testing in all EC (III, B); molecular classification needs all four surrogate tests.
- ABS compendium of gynecologic HDR brachytherapy fractionationCervix HR-CTV D90 goal 85-95 Gy EQD210; no single optimal HDR scheme for any site; doses >7 Gy/fx flagged for higher complication risk.
- Radiosurgery Society guide to localized prostate SBRTCase-based RSS guide to intact-prostate SBRT (≤5 fx): large gland, high baseline IPSS and prior TURP are not contraindications if OAR constraints are met.
- ESTRO ACROP Delphi: salvage SBRT for intraprostatic relapseConsensus on only 14/40 items (35%) after 3 Delphi rounds; dose, fractionation, biopsy need and cumulative OAR constraints remain unresolved.
- ASCO guideline: imaging for advanced prostate cancerNGI should be offered when salvage RT is contemplated after RP (evidence high, strong). Withhold it when no salvage local therapy is planned.
- ASCO-ASTRO-SSO Hereditary Breast Cancer GuidelineJoint consensus guideline: RT should not be withheld in BRCA1/2, ATM or other moderate-penetrance carriers; intact-breast RT is contraindicated in germline TP53 carriers.
- ASTRO-ASCO-SSO PMRT GuidelinePMRT is recommended for pN1, any pT4, ypN1 and cT4/cN2-3 after NST, and conditional for pT3N0 and cT1-3N1/cT3N0 ypN0. Moderate hypofractionation is preferred.
- HyTEC Vestibular Schwannoma SRS TCPPooled LQ model of 35 series (5162 pts) predicts 3-5y TCP 91.2% at 12 Gy and 93.5% at 13 Gy single-fraction SRS.
- LINAC SRS: DCA vs VMAT Dosimetric StudyPaddick CI 0.78 VMAT vs 0.75 DCA+SSO+VDR (p=0.03); GI and V12Gy not different between the two; VMAT ~41 ± 17% more MU.
- HyTEC Adrenal SBRT TCP1-yr LC >95% predicted at BED10 116.4 Gy (EQD2 ~97 Gy) in a Poisson TCP fit to published adrenal metastasis SBRT series.
- DCAT vs CoVMAT vs NcVMAT for single brain metastasis (planning study)Non-coplanar VMAT gave the lowest normal-brain V12Gy (9.4 vs 11.6 DCAT vs 15.1 cm3 coplanar VMAT) for 2-3 cm single BM SRS plans.
- Elements MME vs RapidArc single-isocenter SRS plan qualityRapidArc VMAT gave lower V12Gy (19.2 vs 23.7 cm3) and better conformity; Elements MME gave lower V5Gy and mean brain dose (2.57 vs 2.76 Gy).